FDA Approves Ocrevus for Pediatric Relapsing-Remitting Multiple Sclerosis Patients

Relapsing-remitting multiple sclerosis (MS) is a form of MS for which Ocrevus intravenous (IV) infusion is now FDA-approved for treating children 10+ who weigh at least 55 lbs. (25 kg). The approval is a significant milestone in MS treatment for kids, providing a potentially effective treatment option.

Expanding High-Efficacy MS Treatment for Children

The FDA approval was based on the efficacy of Ocrevus from the OPERATTARETTA II study, which showed it to be non-inferior to Fingolimod in the measure of annualised relapse rate (ARR). The safety profile observed in the pediatric population was similar to that in adult trials, with serious adverse events and infections relatively rare and evenly distributed across the group.

Levi Garraway, M.D., PhD, Genentech's chief medical officer and global head of product development, noted the approval was an important milestone for families of children who get MS. He stressed a 10-year track record of efficacy and safety data had the potential to limit relapses and improve long-term outcomes for younger MS patients.

According to Precedence Research, the Multiple Sclerosis Therapeutics Market size was calculated at USD 34.80 billion in 2025 and is predicted to increase from USD 37.16 billion in 2026 to approximately USD 66.80 billion by 2035, expanding at a CAGR of 6.90% from 2026 to 2035, due to the widespread occurrence of autoimmune neurological disorders, the adoption rate of biologic drugs, and the need for other advanced disease-modifying drugs.

Industry Impact and Outlook

Ocrevus' approval for RRMS kids implies Genentech and Roche's role in the worldwide MS therapeutics market. The early intervention and individualized treatment protocols, or "Pediatric Neurology Extension," reflect a general industry trend toward early intervention and individualized treatment programs for neurological disorders.

The approval also highlights the shift in the paradigm of MS treatments since there are more high-efficacy therapies available to people of all ages. This shift towards earlier diagnosis and therapy will have significant implications globally in the future for paediatric neurological management due to the use of advanced treatments such as Ocrevus.